Imagine popping a pill and effectively turning back your biological clock by a decade. Harvard biologist David Sinclair, a name synonymous with longevity research, isn't just imagining it. He's planning to test an oral "reprogramming" drug on human volunteers, all part of a high-stakes, $101 million XPrize competition.
His candidate, code-named SL-100, is designed to mimic the genetic wizardry of embryos. That's right, the kind of genes that can transform adult cells into their more youthful, stem-cell counterparts. The grand ambition here isn't just a facial cream; it's a full-body reset, targeting the epigenetic marks on your DNA that essentially tell your cells how old they are and how to behave.
While other companies are dabbling in rejuvenation—Sinclair's own Life Biosciences has a gene therapy trial for eye conditions—this new venture is decidedly more audacious. We're talking about a pill that could potentially ripple through your entire system, not just a specific organ. Sinclair confirms extensive animal studies are underway, with the ultimate goal of finding "evidence for age restoration in humans" via the XPrize.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxThe Race to Rewind the Clock
The XPrize Healthspan Competition, which kicked off in 2023 with funding from Saudi Arabia’s Hevolution Foundation, is offering serious cash to teams who can prove they can "restore" a person to a younger biological age. The metrics? Improvements in immune function, cognitive sharpness, and muscle strength. The ultimate prize goes to whoever can demonstrate a 10-year age reversal in just one year of treatment. Which, if you think about it, is both impressive and slightly terrifying.
Sinclair's team is a late entry, but they're aiming to begin human trials this year. They're up against 65 other teams exploring everything from specialized health foods and lifestyle tweaks to digital trackers and, of course, other drug compounds. Jamie Justice, the executive director of the contest, isn't sugarcoating it: finding a winner will be incredibly difficult.
Of course, not everyone is uncorking the champagne just yet. Sergiy Velychko, founder of Soxogen, points out that the chemicals used in this kind of reprogramming are often deployed in high, sometimes harsh, concentrations in labs. Sinclair himself is keeping the exact ingredients of SL-100 a closely guarded secret, though he's previously published work on "epigenetic age-reversal cocktails" that included a mix of powerful chemicals, known supplements, and even existing medicines. James Clement, head of Betterhumans, has confirmed he's running clinical trials for Sinclair's XPrize team, using an oral cocktail.
Past attempts haven't always been smooth sailing. Another Harvard biologist, Vadim Gladyshev, found that low concentrations of rejuvenating compounds in mice did nothing, while high concentrations were flat-out toxic. It seems the sweet spot for de-aging is a rather narrow target.
Perhaps the biggest hurdle in the entire field is the lack of a universally agreed-upon way to measure aging, let alone its reversal. Justice hopes the XPrize itself will help standardize these measurements, potentially paving the way for regulatory approval of future anti-aging drugs. The finalists for this fascinating (and frankly, a little sci-fi) competition will be announced in August. Let's see if we're all about to get a decade back.
